Targets › VZVA
1 program from 1 company in 4 trials: 2 Phase 2, 2 Phase 1; Infectious disease.
Open in Phaseline: the race on VZVA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MAXVAX Biotechnology Limited Liability Company | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 Recombinant varicella zoster virus glycoprotein E vaccine with low dose MA105 adjuvant | VZV, VZVA | Phase 2 | Herpes Zoster | – |
Herpes Zoster (4)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.